(Q54958322)

13 June 2018

title

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. (English)

1 reference

13 June 2018

0 references

11

Paul Aisen

1 reference

13 June 2018

Hong Liu-Seifert

1

1 reference

13 June 2018

Eric Siemers

2

1 reference

13 June 2018

Karen C Holdridge

3

1 reference

13 June 2018

Scott W Andersen

4

1 reference

13 June 2018

Ilya Lipkovich

5

1 reference

13 June 2018

Christopher Carlson

6

1 reference

13 June 2018

Gopalan Sethuraman

7

1 reference

13 June 2018

Sharon Hoog

8

1 reference

13 June 2018

Roza Hayduk

9

1 reference

13 June 2018

Rachelle Doody

10

1 reference

13 June 2018

publication date

26 July 2015

1 reference

13 June 2018

Alzheimer's & dementia (New York, N. Y.)

published in

1 reference

13 June 2018

volume

1

1 reference

13 June 2018

issue

2

1 reference

13 June 2018

page(s)

111-121

1 reference

13 June 2018

A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

Disease-modifying treatments for Alzheimer's disease

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

Slowing the progression of Alzheimer disease: methodologic issues.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

FDA: evidentiary standards for drug development and approval

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975050

10.1016/J.TRCI.2015.06.006

13 August 2018

Identifiers

DOI

1 reference

13 June 2018

PMC publication ID

5975050

1 reference

13 June 2018

PubMed publication ID

29854931

1 reference

13 June 2018